Home Cart Sign in  
Chemical Structure| 749886-87-1 Chemical Structure| 749886-87-1

Structure of JSH-23
CAS No.: 749886-87-1

Chemical Structure| 749886-87-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

JSH-23 is an NF-κB inhibitor that suppresses NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. It inhibits the nuclear translocation of NF-κB p65 without affecting IκBα degradation.

Synonyms: NF-κB Activation Inhibitor II

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of JSH-23

CAS No. :749886-87-1
Formula : C16H20N2
M.W : 240.34
SMILES Code : NC1=CC(C)=CC=C1NCCCC2=CC=CC=C2
Synonyms :
NF-κB Activation Inhibitor II
MDL No. :MFCD09753595
InChI Key :YMFNPBSZFWXMAD-UHFFFAOYSA-N
Pubchem ID :16760588

Safety of JSH-23

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of JSH-23

pyroptosis

Isoform Comparison

Biological Activity

Description
JSH-23 functions as an NF-κB inhibitor, effectively suppressing NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. It achieves this by impeding the nuclear translocation of NF-κB p65 without impacting IκBα degradation[1].
Target
  • NF-κB

    NF-κB, IC50:7.1 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
primary hepatocytes from WT mice 20 µM 6 h JSH-23 inhibited LPS-induced upregulation of caspase-11 mRNA and protein expression PMC8261017
L428 cells 100 μM 24 h Inhibited IL-6 secretion PMC5287295
PAM212 keratinocytes 20 µM 2 h JSH-23 reduced the TWEAK-enhanced Ro52 expression, indicating that the NF-κB pathway is involved in the TWEAK regulation of Ro52. PMC5449764
T98G cells 200 µM 48 h To evaluate the effect of JSH-23 on T98G cells, results showed that JSH-23 significantly inhibited cell proliferation and induced apoptosis. PMC9082891
LN229 cells 200 µM 48 h To evaluate the effect of JSH-23 on LN229 cells, results showed that JSH-23 significantly inhibited cell proliferation and induced apoptosis. PMC9082891
BMMs 25 μM 6 h JSH-23 inhibits NF-κB signaling pathway, reducing VEGF-C expression PMC4773521

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice CLP-induced sepsis model intraperitoneal injection 20 mg/kg 2 hours before CLP and 12, 24, 48, and 72 hours after CLP To evaluate the therapeutic effect of JSH-23 on sepsis, the results showed that JSH-23 improved organ injury but did not significantly improve survival rate PMC9334269
mice MCD-induced NASH model oral gavage 3 mg/kg once daily for 4 weeks JSH-23 prevented MCD-induced upregulation of caspase-11 mRNA and protein expression PMC8261017
Mice Trauma-induced heterotopic ossification model Intraperitoneal injection 3 mg/kg Once daily for 3 weeks To evaluate the effect of JSH-23 on trauma-induced heterotopic ossification. The results showed that JSH-23 significantly reduced the senescent cell burden at the injury site and inhibited the eventual heterotopic ossification formation. PMC10323626
BALB/c nude mice tumor xenograft model intraperitoneal injection 5 mg/kg once daily for 15 days To investigate whether PBK enhances olaparib resistance in ovarian cancer through the NF-κB pathway, results showed that JSH-23 blocked the resistance induced by PBK overexpression PMC9355941
Nude mice GBM xenograft model Intraperitoneal injection 25 mg/kg Every 2 days for 21 days To evaluate the effect of JSH-23 on the GBM xenograft model, results showed that JSH-23 significantly inhibited tumor growth. PMC9082891
Mice Mmp14/C0//C0 mice Intraperitoneal injection 10 mg/kg Daily for 12 days JSH-23 significantly reduces corneal lymphangiogenesis in Mmp14/C0//C0 mice by inhibiting NF-κB signaling pathway PMC4773521

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.16mL

0.83mL

0.42mL

20.80mL

4.16mL

2.08mL

41.61mL

8.32mL

4.16mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories